Therapeutic inhibition of excessive lung inflammation induced by anti-SARS-CoV-2 antibodies

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.043E+13

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $332,902.86
  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)
  • Principle Investigator

    Pending
  • Research Location

    Netherlands, Europe
  • Lead Research Institution

    Amsterdam University Medical Center - location AMC
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Project description In critically ill COVID-19 patients, pneumonia is associated with very strong inflammatory reactions, which can lead to multiple organ failure and eventual death. The current treatment options for the critically ill COVID-19 patients are unfortunately limited. Since the development and distribution of a vaccine will take one to two years, there is an urgent need for treatment for this category of most ill patients. Research and expected outcomes This study will investigate the underlying reason for these severe inflammatory reactions and will test which possible treatment options (drugs) can counteract these extreme inflammatory reactions. The findings indicate that critically ill COVID-19 patients produce a different kind of antibody against the virus, which in turn triggers the extreme inflammatory response. This could explain why this group of patients deteriorates so much after about a week and a half.